Association of a comprehensive geriatric assessment and toxicity, overall survival and quality of life

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00012532

Enrollment

534

Registered

2017-10-13

Start date

2018-04-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geriatric tumour patients receiving chemotherapy

Interventions

Group 1: Fit and vulnerable assessed patients from the geriatric-oncologic conference receive chemotherapy and regularly scheduled visits with regard to toxicity and quality of life. Additionally, the

Eligibility

Sex/Gender

All

Age

65 Years to No maximum

Inclusion criteria

Inclusion criteria: -Patient with histologically confirmed carcinoma or histologically confirmed aggressive B-NHL -First diagnosis of cancer -Age 65 years and above -Estimated life expectancy of at least 3 months -Informed consent -Judged fit or vulnerable by assessment of the geriatric-oncologic conference OR -Judged Unfit by assessment of the geriatric-oncologic conference

Exclusion criteria

Exclusion criteria: -Patients with leukemia, indolent lymphoma -Previous chemotherapy -Unwillingness of the patient to undergo a geriatric assessment -Imminent dialysis -Brain metastasis -Acute coronary syndrome within the last 3 months -Unwillingness to participate in regular follow-up visits

Design outcomes

Primary

Measure	Time frame
Measurement of toxicity (after Common Toxicity Criteria for Adverse Events 4.0 at every visit) with regard to the assessment of the geriatric-oncologic conference after the geriatric assessment	—

Secondary

Measure	Time frame
-Recognition of overall survival as a function of geriatric assessment and assessment of the geriatric-oncological conference -Consideration of the quality of life (every six weeks after EORTC QLQ-C30) as a function of geriatric assessment and the assessment of the geriatric-oncologic conference -Consideration of the modification of assessment parameters during cytostatic chemotherapy -Assessment of a primary dose modification of chemotherapy as a function of geriatric assessment and the assessment of the geriatric-oncologic conference -recognition of the rate of unfit patients who are treated by additional geriatric interventions and get fit or vulnerable as assessed of the geriatric-oncologic conference	—

Measure

Time frame

-Recognition of overall survival as a function of geriatric assessment and assessment of the geriatric-oncological conference -Consideration of the quality of life (every six weeks after EORTC QLQ-C30) as a function of geriatric assessment and the assessment of the geriatric-oncologic conference -Consideration of the modification of assessment parameters during cytostatic chemotherapy -Assessment of a primary dose modification of chemotherapy as a function of geriatric assessment and the assessment of the geriatric-oncologic conference -recognition of the rate of unfit patients who are treated by additional geriatric interventions and get fit or vulnerable as assessed of the geriatric-oncologic conference

—

Countries

Germany

Contacts

Public ContactSebastian Ertl

Kliniken Essen-MitteKlinik für internistische Onkologie mit integrierter Palliativmedizin

s.ertl@kliniken-essen-mitte.de020117424001

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026